Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05767736 · ClinicalTrials.gov registry record
A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
A clinical trial of Multiple Sclerosis, sponsored by Biogen.
- Active
- Registry status
- 10,500
- Enrollment target
- 1
- Study location
NCT05767736 is a study of Multiple Sclerosis that is active but no longer recruiting, run by Biogen. The registered enrollment target is 10,500 participants, above the 552-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (1802% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05767736, a study of Multiple Sclerosis, is active but no longer recruiting, sponsored by Biogen.
- ACTIVE NOT RECRUITING
- Registry status
- 10,500 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of the study is to estimate the incidence rate of serious adverse events (SAEs), including but not limited to malignancies and serious and opportunistic infections, among participants with MS treated with Vumerity, Tecfidera, other selected disease modifying therapies (DMTs \[teriflunomide, beta interferons, or glatiramer acetate\]), or Vumerity after switching from Tecfidera. The secondary objective of the study is to compare the incidence rate of SAEs, including but not limited to malignancies and serious and opportunistic infections, among MS participants treated with Vumerity, Tecfidera, and Vumerity after switching from Tecfidera with the incidence rate of MS participants treated with other selected DMTs (teriflunomide, beta-interferons, or glatiramer acetate), if the sample size allows.
Conditions Studied
Interventions
- DRUG Diroximel Fumarate
- DRUG Dimethyl Fumarate
- DRUG Disease-Modifying Therapies (DMTs)
Study Locations (1)
Massachusetts
- Research Site - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,500 participants |
| Start Date | 2024-06-08 |
| Est. Completion | 2032-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05767736
The ClinicalTrials.gov registry entry for NCT05767736 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 10,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 552-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (1802% higher). The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 3 interventions - of which Diroximel Fumarate is the first listed.
NCT05767736 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05767736 about?
NCT05767736 is a clinical study titled "A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)". The primary objective of the study is to estimate the incidence rate of serious adverse events (SAEs), including but not limited to malignancies and serious and opportunistic infections, among participants with MS treated with Vumerity, Tecfidera, other selected disease modifying therapies (DMTs \[t...
What is the current status of trial NCT05767736?
This trial is currently active not recruiting. The enrollment target is 10,500 participants. The study started on 2024-06-08. Estimated completion is 2032-12-01.
What conditions does trial NCT05767736 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT05767736?
The interventions under investigation include: Diroximel Fumarate (DRUG), Dimethyl Fumarate (DRUG), Disease-Modifying Therapies (DMTs) (DRUG).
Who is sponsoring clinical trial NCT05767736?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05767736 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.